Lundbeck launches Brintellix in Denmark
Danish CNS drug specialist Lundbeck (LUN: CO) is debutting its new antidepressant Brintellix (vortioxetine) in Denmark, representing the first European launch for the drug which was commercially released in the USA in January 2014.
Brintellix, approved for treatment of major depressive episodes in adults, will be introduced in several other European and international markets in 2014 and 2015, the company said.
It is a multimodal antidepressant which has demonstrated significant efficacy in adult patients with depression as measured by traditional scales, and has demonstrated improvement of cognitive performance. Cognitive symptoms, part of the diagnostic criteria for depression, include concentration, decision-making and memory.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze